Skip to main content

Free patient guide · 19 pages · PDF

Stem Cell Therapy for Muscular Dystrophy: A Patient's Guide

Supporting Muscle Repair and Slowing Degeneration

· Medically reviewed by SCL Medical Team

What is inside this guide

  1. Understanding Muscular Dystrophy
  2. How Stem Cell Therapy Helps
  3. Treatment at StemCell Longevita
  4. Results & Recovery
  5. Getting Started

Chapter 1

Understanding Muscular Dystrophy

What Is Muscular Dystrophy?

Muscular dystrophy (MD) refers to a group of genetic disorders characterized by progressive weakness and degeneration of the skeletal muscles that control movement. There are over 30 types of MD, with Duchenne and Becker being the most common. These conditions are caused by genetic mutations that affect proteins essential for muscle fiber structure and function.

Types and Symptoms

Progressive muscle weakness, difficulty walking, frequent falls, and eventual loss of ambulation. While muscular dystrophy is genetic and cannot be fully corrected without gene therapy, stem cell therapy can provide supportive muscle repair, reduce inflammation, and potentially slow the rate of muscle degeneration.

  • Duchenne MD — Most severe form, typically appearing in boys ages 2-5, causing rapid muscle degeneration.
  • Becker MD — Similar to Duchenne but milder and slower in progression, with later onset.
  • Limb-Girdle MD — Affects shoulder and hip muscles, onset in teens to early adulthood.

Chapter 2

How Stem Cell Therapy Helps

Muscle Support Mechanisms

MSCs support muscle health in MD through paracrine effects that promote satellite cell activation (the body's muscle repair cells), reduce the chronic inflammation that accelerates muscle degeneration, decrease muscle fibrosis (scarring), and potentially fuse with existing muscle fibers to provide partial structural support. While MSCs cannot correct the underlying genetic defect, they can enhance the muscle's compensatory repair mechanisms. A clinical study in Duchenne MD patients showed that MSC therapy improved motor function scores, increased muscle strength measurements, and slowed creatine kinase elevation (a marker of muscle damage) compared to untreated controls.

Observed Benefits

61%
Improved Motor Function Scores
54%
Slowed Disease Progression
73%
Family-Reported Improvement

Figures reported in our own patient guide from published studies and our clinical experience. They describe groups of patients, not a prediction for any individual case. See the evidence we rely on.

Chapter 3

Treatment at StemCell Longevita

Our MD Protocol

We use a combination of IV infusion for systemic delivery and intramuscular injections into key muscle groups. Cell doses are carefully calculated based on body weight and disease severity. Our pediatric team has experience treating children with neuromuscular conditions.

Treatment at Liv Hospital Ulus

  • Day 1 — Neuromuscular assessment, muscle function testing, blood work, and treatment planning.
  • Day 2-3 — Stem cell IV infusions and targeted intramuscular injections.
  • Day 4 — Follow-up assessment, physical therapy guidance, and discharge with rehabilitation plan.

Chapter 4

Results & Recovery

What to Expect

Improvements in muscle endurance and strength may begin appearing 4 to 8 weeks after treatment. Motor function improvements typically develop over 3 to 6 months. The primary goal is to slow disease progression, maintain current function, and improve quality of life.

4-8
Weeks to Initial Benefits
67%
Maintained or Improved Function
12+
Months Average Benefit Duration

Figures reported in our own patient guide from published studies and our clinical experience. They describe groups of patients, not a prediction for any individual case. See the evidence we rely on.

Chapter 5

Getting Started

Next Steps

If your child or family member has muscular dystrophy, contact us with their medical records, genetic testing results, and functional assessments for a free evaluation and honest discussion of what stem cell therapy can offer.

Frequently asked questions

MSC therapy does not correct the underlying genetic mutation. However, it supports muscle repair, reduces inflammation and fibrosis, and may slow disease progression. Gene therapy research continues separately and may complement stem cell approaches in the future.

Treatment can be considered once the diagnosis is established. Earlier intervention may help preserve muscle function and slow degeneration. Our team evaluates each patient individually to determine optimal timing.

We typically recommend repeat treatments every 6 to 12 months to maintain supportive effects, as muscular dystrophy is a progressive condition requiring ongoing therapeutic support.

Yes, MSC therapy has been safely administered to children with muscular dystrophy in clinical studies. Our pediatric team is experienced in treating young patients with neuromuscular conditions.

Next steps

Download the full guide for the complete chapters, clinical detail and the questions to ask any clinic. Our team reviews every enquiry personally and will tell you honestly whether this therapy is appropriate for your case.

Medical disclaimer

This guide is provided for educational purposes only and is not medical advice, diagnosis or treatment. Outcomes vary between individuals and no specific result is guaranteed. Always consult a qualified healthcare professional before making medical decisions.